AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11016021
Drug: Lysine acetylsalicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine acetylsalicylate (LA) 320 mg
Trial: 2939219
Drug: Ketanserin (K),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (K), 40 mg twice daily
Trial: 2939219
Drug: Metoprolol (M),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (M), 100 mg twice daily
Trial: 30027406
Drug: Hexanic extract
RxNorm normalized name: hexane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexanic extract of Serenoa repens (HESr) 320 mg/day
Trial: 20684401
Drug: Various strategies
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various strategies to avoid physician's inertia and combat patient's non-compliance, including titration, rescue medications, and self-monitoring.
Trial: 20684401
Drug: Pill count
RxNorm normalized name: Pill Counting Tray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill count for compliance verification during the placebo run-in period.
Trial: 17432675
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group treated with anti‐anxiety drugs
Trial: 11305823
Drug: Dopexamine infusion
RxNorm normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopexamine infusion (0.5 - 2 microg x kg(‐1) x min(‐1))
Trial: 11305823
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo infusion)
Trial: 2894232
Drug: Aspirin 600
RxNorm normalized name: aspirin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 600 mg twice daily
Trial: 30484837
Drug: Mineralocorticoid antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Mineralocorticoid antagonists
Trial: 26200278
Drug: Cabazitaxel 25
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel 25 mg/m every 21 days
Trial: 26200278
Drug: Topotecan 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 1.5 mg/m on days 1-5 every 21 days
Trial: 22610788
Drug: sGC-RT (sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sGC-RT (sequential CRT with gemcitabine and cisplatin)
Trial: 22610788
Drug: Con-RT (cisplatin-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Con-RT (cisplatin-based concurrent chemoradiotherapy plus adjuvant PF chemotherapy)
Trial: 18212696
Drug: Milrinone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (0.5 microg/kg/min infusion)
Trial: 17021320
Drug: AIC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIC vaccine
Trial: 9085959
Drug: Tourniquet kept
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tourniquet kept inflated for 10 min after I.A. injection of morphine (5 mg in 25 mL saline)
Trial: 9085959
Drug: Tourniquet deflated
RxNorm normalized name: panthenol
DrugBank: Panthenol (DB11204)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tourniquet deflated immediately after I.A. injection of morphine (5 mg in 25 mL saline)
Trial: 1492861
Drug: Dihydroergocristine (DHEC)
RxNorm normalized name: Dihydroergocristine
DrugBank: Dihydroergocristine (DB13345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergocristine (DHEC) 1.5 mg/d
Trial: 1492861
Drug: Dihydroergocristine (DHEC)
RxNorm normalized name: Dihydroergocristine
DrugBank: Dihydroergocristine (DB13345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergocristine (DHEC) 3 mg/d
Trial: 1492861
Drug: Dihydroergocristine (DHEC)
RxNorm normalized name: Dihydroergocristine
DrugBank: Dihydroergocristine (DB13345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergocristine (DHEC) 6 mg/d
Trial: 4080903
Drug: Alcohol (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.8 ml of pure alcohol per kg body weight)
Trial: 31208470
Drug: Auricular acupressure
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular acupressure treatment once per week for 4 weeks and calcipotriol betamethasone ointment once daily for 4 weeks
Trial: 31208470
Drug: Calcipotriol betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcipotriol betamethasone ointment once daily for 4 weeks
Trial: 23110952
Drug: Bromocriptine (Bc;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (Bc; 16 mg/heifer)
Trial: 23110952
Drug: Acyline (Ac;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyline (Ac; 3 μg/kg)
Trial: 20429818
Drug: Brimonidine/timolol fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine/timolol fixed combination (BrTFC) twice daily for 6 weeks
Trial: 20429818
Drug: Dorzolamide/timolol fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide/timolol fixed combination (DTFC) twice daily for 6 weeks
Trial: 18373654
Drug: Baclofen 10
RxNorm normalized name: baclofen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen 10 mg four times per day
Trial: 15661416
Drug: Endourethral macroplastique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endourethral macroplastique injection
Trial: 12442916
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (67 mg/m2/week)
Trial: 12442916
Drug: Every 3
RxNorm normalized name: Eligard Every 3 Months 22.5 MG per 0.375 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 3 weeks paclitaxel (72.7 mg/m2/week)
Trial: 1777370
Drug: Enzyme-inducing anticonvulsants
RxNorm normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enzyme-inducing anticonvulsants (carbamazepine, phenobarbitone or phenytoin)
Trial: 6094457
Drug: Cefotaxime (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (50 mg/kg/im route)
Trial: 30321268
Drug: Fact Box
RxNorm normalized name: ALLERGENIC EXTRACT, BOX ELDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fact Box decision support tools on antibiotics for pneumonia and artificial hydration in advanced dementia (at 1‐month)
Trial: 28889759
Drug: Nintedanib with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib with add-on pirfenidone (titrated to 801 mg three times daily)
Trial: 28889759
Drug: Nintedanib alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib alone (150 mg twice daily)
Trial: 22109997
Drug: Oral rapamycin
RxNorm normalized name: kanamycin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rapamycin plus bare-metal stent (OR + BMS)
Trial: 19395185
Drug: Radiation Therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation Therapy (RT) 10 Gy
Trial: 19395185
Drug: Radiation Therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation Therapy (RT) 20 Gy
Trial: 19395185
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with doxorubicin (three drugs)
Trial: 19395185
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with dactinomycin and vincristine (two drugs)
Trial: 3891710
Drug: amoxycillin 250
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amoxycillin 250 mg three times a day for seven days
Trial: 3891710
Drug: trimethoprim 200
RxNorm normalized name: trimethoprim 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimethoprim 200 mg twice a day for seven days
Trial: 30861997
Drug: Dietary fiber
RxNorm normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fiber intake ≥35 g (n = 15)
Trial: 18267042
Drug: A single
RxNorm normalized name: Hemoccult Sensa Single Slide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of sulphadoxine/pyrimethamine (25 mg/kg of sulphadoxine/1.25 mg/kg of pyrimethamine)
Trial: 18267042
Drug: Amodiaquine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine (10 mg/kg/day x 3 days)
Trial: 16285277
Drug: Ondansetron (8‐12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8‐12 mg orally per day)
Trial: 8824473
Drug: Conventional formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional formulation of cyclosporine
Trial: 1575336
Drug: Low-dose propofol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose propofol (0.08 mg/kg loading dose and 0.5 mg.kg‐1.h‐1 infusion)
Trial: 1575336
Drug: Moderate-dose propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate-dose propofol (0.16 mg/kg loading dose and 1.0 mg.kg‐1.h‐1 infusion)
Trial: 1575336
Drug: High-dose propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose propofol (0.32 mg/kg loading dose and 2.0 mg.kg‐1.h‐1 infusion)
Trial: 3914701
Drug: Piroxicam at
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicam at 20 mg per day
Trial: 3914701
Drug: Ibuprofen at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen at 2,400 mg per day
Trial: 20633037
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 100 mg/day starting on day 1
Trial: 20633037
Drug: Phenytoin (PHT)
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin (PHT) 1,000 mg on day 1 followed by 300 mg/day maintenance
Trial: 17127586
Drug: Protein supplement
RxNorm normalized name: PROTEIN SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplement (2 g x kg(‐1) body mass x day(‐1))
Trial: 17127586
Drug: Whole-body low-magnitude
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body low-magnitude (3.5 g), low-frequency (30 Hz) mechanical vibration (WBV) for 10 min each day
Trial: 17127586
Drug: Protein supplement
RxNorm normalized name: PROTEIN SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplement (2 g x kg(‐1) body mass x day(‐1)) + WBV
Trial: 11712935
Drug: Conservative strategy
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative strategy of medical treatment and predischarge exercise tolerance testing (n = 1106)
Trial: 11712935
Drug: Early invasive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early invasive strategy for patients with cTnI levels of 0.1 ng/mL or more (n = 1087)
Trial: 11712935
Drug: Conservative strategy
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative strategy for patients with cTnI levels of less than 0.1 ng/mL
Trial: 11712935
Drug: Early invasive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early invasive strategy for patients with low-level (0.1-0.4 ng/mL) cTnI elevation
Trial: 9130895
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist and FSH
Trial: 8221426
Drug: Acetaminophen half
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen half dose (162.5 mg per capsule, 2 capsules)
Trial: 8221426
Drug: Acetaminophen full
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen full dose (325 mg per capsule, 2 capsules)
Trial: 8221426
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 identical capsules)
Trial: 3310451
Drug: Immunoglobulin therapy
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin therapy
Trial: 25143169
Drug: Dezoxine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dezoxine 0.1 mg×kg(‐1) and dexmedetomidine 0.4 µg×kg(‐1)×h(‐1) until the end of the first ocular muscle correcting
Trial: 10492055
Drug: Salmeterol dry
RxNorm normalized name: salmeterol Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol dry powder, 50 microg twice daily
Trial: 10492055
Drug: Formoterol dry
RxNorm normalized name: aclidinium / formoterol Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol dry powder, 12 microg twice daily
Trial: 8610621
Drug: Combination lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination lovastatin and probucol
Trial: 2015146
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine (with adrenaline) 3 mg/kg body weight (Group A)
Trial: 2015146
Drug: 0.5% plain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% plain bupivacaine 3 mg/kg body weight (Group B)
Trial: 6123635
Drug: Cereal-based electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cereal-based electrolyte solution (30 g rice powder per litre)
Trial: 6123635
Drug: Standard sucrose‐electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sucrose‐electrolyte solution
Trial: 10961474
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg acetylsalicylic acid (ASA)
Trial: 3839446
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg ciramadol
Trial: 3839446
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ciramadol
Trial: 3839446
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg ciramadol
Trial: 2885928
Drug: Famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg at night
Trial: 25796150
Drug: Traditional Shangke
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional Shangke Jiegu tablets
Trial: 20739691
Drug: Joint mobilization
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint mobilization self‐exercise treatment
Trial: 16701922
Drug: Enriched milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enriched milk (500 cm³ per day) with 5.7 g of oleic acid, 0.2 g of omega-3 fatty acid, 150 µg of folic acid, and 7.5 mg of vitamin E
Trial: 12673463
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of pure natural honey (20 ml before, after, and 6 hours post-radiation therapy)
Trial: 18485252
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of pure natural honey
Trial: 2580172
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg) while fasting
Trial: 2580172
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg) after eating
Trial: 2580172
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg twice a day for 3-12 months) taken 1 h before eating
Trial: 2580172
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg twice a day for 3-12 months) taken during or immediately after eating
Trial: 31775406
Drug: Local intradermal
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local intradermal BTX-A injection
Trial: 26658447
Drug: Hyperglycemia (>140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemia (>140 mg/dL)
Trial: 26658447
Drug: Normoglycemia (≤140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normoglycemia (≤140 mg/dL)
Trial: 26658447
Drug: Higher glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher glucose levels (per 10 mg/dL increase) in patients with incomplete reperfusion
Trial: 9235005
Drug: 0.075 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075 mg/kg atracurium
Trial: 9235005
Drug: 0.0125 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0125 mg/kg pancuronium followed by 0.45 mg/kg atracurium
Trial: 27413070
Drug: Recombinant fusion
RxNorm normalized name: Recombinant fusion protein of Mycobacterium bovis BCG Hsp65 and HPV16 E7
DrugBank: Verpasep caltespen (DB04959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant fusion protein ESAT6-CFP10 (1, 5, 10, or 20 μg/ml)
Trial: 25715786
Drug: Continuous local
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous local anaesthetic infusion via wound infusion catheter (WIC)
Trial: 23810678
Drug: Azathioprine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (2.5 mg/kg/day)
Trial: 6161689
Drug: SCAB chemotherapy
RxNorm normalized name: Scab-wort Root
DrugBank: Inula helenium root (DB14350)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCAB chemotherapy (streptozocin, lomustine, doxorubicin hydrochloride, and bleomycin sulfate)
Trial: 6161689
Drug: SCAB chemotherapy
RxNorm normalized name: Scab-wort Root
DrugBank: Inula helenium root (DB14350)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCAB chemotherapy
Trial: 28833562
Drug: ADS-5102 (amantadine)
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ADS-5102 (amantadine) 274 mg once daily at bedtime for 13 weeks
Trial: 26237305
Drug: Water preloading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water preloading (500 ml of water 30 min before meals)
Trial: 23319439
Drug: 3,4-DHPAA and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3,4-DHPAA and EGCG (in vitro treatment)
Trial: 21471566
Drug: Rituximab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1 g in 500 ml of 0.9% saline intravenously over 4 h, n=16)
Trial: 16424644
Drug: 6-week VACOP-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-week VACOP-B followed by high-dose sequential chemotherapy (HDS) and autologous stem cell transplantation (ASCT)
Trial: 11402280
Drug: NSAIDs and
RxNorm normalized name: methenamine
DrugBank: Methenamine (DB06799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NSAIDs and physical therapy
Trial: 8565795
Drug: Pharmacotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy with opioid receptor antagonists naltrexone and nalmefene
Trial: 2233917
Drug: Corticosteroids (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (40 mg of prednisone twice daily)
Trial: 31123852
Drug: Post-operative bladder
RxNorm normalized name: Sus scrofa urinary bladder preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative bladder instillation of chemotherapy
Trial: 31123852
Drug: Platin-based chemotherapy
RxNorm normalized name: platinic chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platin-based chemotherapy for invasive UTUC
Trial: 25224665
Drug: docetaxel-based chemotherapy
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel-based chemotherapy + zoledronic acid (ZA)
Trial: 25224665
Drug: docetaxel-based chemotherapy
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel-based chemotherapy + placebo
Trial: 17442125
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioural therapy (CBT) for PTSD, conducted over a 5-week period (10 sessions)
Trial: 17442125
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioural therapy (CBT) for PTSD
Trial: 16450851
Drug: New experimental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New experimental treatment
Trial: 8435991
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment given by community health centres (conventionally treated group)
Trial: 28905166
Drug: Self-help treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-help treatment including three motivational telephone interviews and a cognitive-behavioral self-help workbook
Trial: 23893066
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) component of the depression prevention program 'Op Volle Kracht' (OVK), 8 lessons
Trial: 23893066
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) component of OVK